Equity Details
Price & Market Data
Price: $0.70
Daily Change: +$0.015 / 2.14%
Daily Range: $0.661 - $0.719
Market Cap: $28,594,224
Daily Volume: 13,239
Performance Metrics
1 Week: 6.87%
1 Month: 27.27%
3 Months: -1.41%
6 Months: -34.58%
1 Year: -24.73%
YTD: -0.01%
About Barinthus Biotherapeutics plc (BRNS)
Explore comprehensive market data for Barinthus Biotherapeutics plc (BRNS). Currently priced at 0.70, observe its daily movement of +$0.015 / 2.14%. The total market value is 28,594,224. Review its performance across various timeframes, including the last week, month, and year, to understand its trajectory.
Company Details
Employees: 14
Sector: Health technology
Industry: Pharmaceuticals: major
Country: United Kingdom
Details
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis B virus infection. It has a license agreement with Oxford University Innovation for the development and commercialization of products with thermo-responsive adjuvant scaffolds; and U.S. National Institutes of Health for the evaluation of synthetic and polymer-based vaccine technology to prevent infectious disease and treat cancer in animal models. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is based in Germantown, Maryland.